These included IPM from Korea (hospital based using gender, HCV infection, HBV infection, AFP levels, chronic hepatitis, cirrhosis, alcohol use and ALT levels) [149]; GAG-HCC risk score from Hong-Kong (hospital based using gender, age, HBV DNA levels, core promoter mutations and cirrhosis) [150]; CUHK clinical scoring system from Hong-Kong (hospital based using age, albumin, bilirubin, HBV DNA levels and cirrhosis) [151]; and REVEAL nomograms from Taiwan (community based using gender, age, ALT levels, family history of HCC, alcohol consumption, HBV DNA levels, HBeAg and HBV genotype) [152]. This evidence concerns the gene GPT and hepatocellular carcinoma.